Given the association between high CXCL5 expression levels and poor prognosis in patients with lung cancer and the autocrine and paracrine roles of CXCL5 in mediating notable immunosuppression and immune evasion, we investigated the combined treatment of lung cancer with dual blockade of CXCL5 and PD-L1. Here, CXCL5 is linked to lung carcinoma.